Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 108

Sort by

Sort Order Select

Journal Articles

RNA Regulator of Lipogenesis (RROL) Is a Novel Lncrna Mediating Protein-Protein Interaction at Gene Regulatory Loci Driving Lipogenic Programs in Multiple Myeloma

Blood (2020) 136 (Supplement 1): 20–21.

https://doi.org/10.1182/blood-2020-142514

Published: 2020

Journal Articles

A High Throughput Quantitative Seroproteomics Analysis of Multiple Myeloma Patients on Tagraxofusp Therapy Identifies Novel Cytokine-Assisted Mechanism of Action

Arghya Ray, PhD, Yan Song, PhD, Ting DU, PhD, Clifton C. Mo, MD, Arturo Olguin, Janice Chen, PhD, Christopher Brooks, PhD, Tariq I. Mughal, MD FRCP, Paul G. Richardson, MD, Dharminder Chauhan, PhD, Kenneth Anderson, MD

Blood (2020) 136 (Supplement 1): 34.

https://doi.org/10.1182/blood-2020-141571

Published: 2020

Journal Articles

Proteomic Characterization of Ubiquitin Receptor ADRM1/Rpn13

Yan Song, PhD, Ting DU, PhD, Arghya Ray, PhD, Krishan Chauhan, Mehmet K. Samur, PhD, Dharminder Chauhan, PhD, Kenneth Anderson, MD

Blood (2020) 136 (Supplement 1): 39.

https://doi.org/10.1182/blood-2020-139966

Published: 2020

Journal Articles

Blockade of Deubiquitylating Enzyme USP7 in Plasmacytoid Dendritic Cells Stimulates Anti-Myeloma Immunity

Arghya Ray, PhD, Ting DU, PhD, Yan Song, PhD, Sara J Buhrlage, PhD, Dharminder Chauhan, PhD, Kenneth Anderson, MD

Blood (2020) 136 (Supplement 1): 43.

https://doi.org/10.1182/blood-2020-138591

Published: 2020

Journal Articles

Analysis of Sars-Cov-2-Associated Proteins Identify Tank-Binding Kinase-1 As an Immunotherapeutic Target in Multiple Myeloma

Arghya Ray, PhD, Ting DU, PhD, Krishan Chauhan, Yan Song, PhD, Dharminder Chauhan, PhD, Kenneth Anderson, MD

Blood (2020) 136 (Supplement 1): 29–30.

https://doi.org/10.1182/blood-2020-143393

Published: 2020

Journal Articles

Bortezomib Induces Anti-Multiple Myeloma Immune Response Mediated By Cgas/Sting Pathway Activation, Type I Interferon Secretion, and Immunogenic Cell Death: Clinical Application

Annamaria Gulla, MD, Eugenio Morelli, MD, Mehmet Kemal Samur, PhD, Cirino Botta, MDPhD, Teru Hideshima, MD PhD, Giada Bianchi, MD, Mariateresa Fulciniti, PhD, Stefano Malvestiti, MD, Rao Prabhala, Srikanth Talluri, PhD, Yu-Tzu Tai, PhD, Kenneth Wen, Paul G. Richardson, MD, Ruben D. Carrasco, MD PhD, Dharminder Chauhan, PhD, Nikhil C. Munshi, MD, Kenneth Anderson, MD

Blood (2020) 136 (Supplement 1): 7–8.

https://doi.org/10.1182/blood-2020-140356

Published: 2020

Journal Articles

Proteomic Analysis Identifies Mechanism(s) of Overcoming Bortezomib-Resistance Via Targeting Ubiquitin Receptor Rpn13

Ting Du, PhD, Yan Song, PhD, Arghya Ray, PhD, Dharminder Chauhan, PhD, Kenneth C. Anderson, MD

Blood (2019) 134 (Supplement_1): 3074.

https://doi.org/10.1182/blood-2019-130236

Published: 2019

Journal Articles

Blockade of Ubiquitin Receptor Rpn13 in Plasmacytoid Dendritic Cells Enhances Anti-Myeloma Immunity

Arghya Ray, PhD, Yan Song, PhD, Ting DU, PhD, Dharminder Chauhan, PhD, Kenneth C. Anderson, MD

Blood (2019) 134 (Supplement_1): 3098.

https://doi.org/10.1182/blood-2019-122901

Published: 2019

Journal Articles

Interaction of Plasmacytoid Dendritic Cells and Myeloma Cells Trigger Tumor Promoting Transcriptional Changes in Multiple Myeloma Cells

Arghya Ray, PhD, Leutz Buon, Yan Song, PhD, Dharminder Chauhan, PhD, Kenneth C. Anderson, MD

Blood (2019) 134 (Supplement_1): 510.

https://doi.org/10.1182/blood-2019-123333

Published: 2019

Journal Articles

Loss-of-Function of Gabarap Impairs Bortezomib-Induced Anti-Tumor Immunity in Multiple Myeloma: Clinical Application

Annamaria Gulla, MD, Eugenio Morelli, MD, Mehmet Kemal Samur, PhD, Teru Hideshima, MD PhD, Giada Bianchi, MD, Mariateresa Fulciniti, PhD, Rao Prabhala, Srikanth Talluri, PhD, Yu-Tzu Tai, PhD, Dharminder Chauhan, PhD, Ruben D. Carrasco, MD PhD, Nikhil C. Munshi, MD, Kenneth C. Anderson, MD

Blood (2019) 134 (Supplement_1): 134.

https://doi.org/10.1182/blood-2019-127845

Published: 2019

Journal Articles

Preclinical Validation of Ubiquitin Receptor PSMD4 As Therapeutic Target in Multiple Myeloma

Yan Song, PhD, Ting DU, PhD, Arghya Ray, PhD, Dharminder Chauhan, PhD, Kenneth C. Anderson, MD

Blood (2019) 134 (Supplement_1): 4403.

https://doi.org/10.1182/blood-2019-122952

Published: 2019

Journal Articles

Preclinical Validation of Alpha-Enolase (ENO1) As a Novel Immunometabolic Target in Multiple Myeloma

Arghya Ray, PhD, Yan Song, PhD, Dharminder Chauhan, PhD, Kenneth C. Anderson, MD

Blood (2019) 134 (Supplement_1): 856.

https://doi.org/10.1182/blood-2019-123328

Published: 2019

Journal Articles

Results from Phase 1/2 Trial of Tagraxofusp in Combination with Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma

Paul G. Richardson, MD, Myo Htut, MD, Cristina Gasparetto, MD, Jeffrey A. Zonder, Thomas G. Martin, III, MD, Janice Chen, PhD, Christopher Brooks, PhD, Peter McDonald, Nicole Rupprecht, Halyna Wysowskyj, Dharminder Chauhan, PhD, Arghya Ray, PhD, Kenneth C. Anderson, MD, Claudia E. Paba-Prada, MD

Blood (2019) 134 (Supplement_1): 3145.

https://doi.org/10.1182/blood-2019-130410

Published: 2019

Journal Articles

Blockade of Ubiquitin Receptor PSMD4/Rpn10 Triggers Cytotoxicity and Overcomes Bortezomib-Resistance in Multiple Myeloma

Yan Song, PhD, Arghya Ray, PhD, Dharminder Chauhan, PhD, Kenneth Anderson, MD

Blood (2018) 132 (Supplement 1): 3211.

https://doi.org/10.1182/blood-2018-99-114767

Published: 2018

Journal Articles

Plasmacytoid Dendritic Cells Trigger Contact-Dependent Tumor Promoting Genetic Alterations in Multiple Myeloma Cells

Arghya Ray, PhD, Leutz Buon, Yan Song, PhD, Dharminder Chauhan, PhD, Kenneth C. Anderson, MD

Blood (2018) 132 (Supplement 1): 244.

https://doi.org/10.1182/blood-2018-99-117887

Published: 2018

Journal Articles

Targeting Tryptophan Catabolic Kynurenine Pathway Enhances Anti-Tumor Immunity and Cytotoxicity in Multiple Myeloma

Arghya Ray, PhD, Yan Song, PhD, Dharminder Chauhan, PhD, Kenneth C. Anderson, MD

Blood (2018) 132 (Supplement 1): 1930.

https://doi.org/10.1182/blood-2018-99-117827

Published: 2018

Journal Articles

OP-106 Horizon — Melflufen Therapy for RRMM Patients Refractory to Daratumumab and/or Pomalidomide; Updated Results and First Report on PFS

Blood (2018) 132 (Supplement 1): 600.

https://doi.org/10.1182/blood-2018-99-113095

Published: 2018

Journal Articles

Identification of Alpha-Enolase (ENO1) As a Novel Immunometabolic Target in Multiple Myeloma

Arghya Ray, PhD, Yan Song, PhD, Dharminder Chauhan, PhD, Kenneth C. Anderson, MD

Blood (2018) 132 (Supplement 1): 594.

https://doi.org/10.1182/blood-2018-99-117757

Published: 2018

Journal Articles

Targeting Proteasome- Associated Ubiquitin Receptor PSMD4/Rpn10 in Multiple Myeloma

Yan Song, PhD, Arghya Ray, PhD, Guoqi Zhang, PhD, Mehmet Kemal Samur, PhD, Nikhil Munshi, MD, Dharminder Chauhan, PhD, Kenneth C Anderson, MD

Blood (2017) 130 (Supplement 1): 3075.

https://doi.org/10.1182/blood.V130.Suppl_1.3075.3075

Published: 2017

Journal Articles

HUWE1 Inhibition As a Therapeutic Strategy to Target MYC in MM

Lisa J Crawford, BSc, PhD, Dharminder Chauhan, PhD, Alexandra E Irvine, PhD FRCPath

Blood (2017) 130 (Supplement 1): 3077.

https://doi.org/10.1182/blood.V130.Suppl_1.3077.3077

Published: 2017

NARROW

RNA Regulator of Lipogenesis (RROL) Is a Novel Lncrna Mediating Protein-Protein Interaction at Gene Regulatory Loci Driving Lipogenic Programs in Multiple Myeloma

A High Throughput Quantitative Seroproteomics Analysis of Multiple Myeloma Patients on Tagraxofusp Therapy Identifies Novel Cytokine-Assisted Mechanism of Action

Proteomic Characterization of Ubiquitin Receptor ADRM1/Rpn13

Blockade of Deubiquitylating Enzyme USP7 in Plasmacytoid Dendritic Cells Stimulates Anti-Myeloma Immunity

Analysis of Sars-Cov-2-Associated Proteins Identify Tank-Binding Kinase-1 As an Immunotherapeutic Target in Multiple Myeloma

Bortezomib Induces Anti-Multiple Myeloma Immune Response Mediated By Cgas/Sting Pathway Activation, Type I Interferon Secretion, and Immunogenic Cell Death: Clinical Application

Proteomic Analysis Identifies Mechanism(s) of Overcoming Bortezomib-Resistance Via Targeting Ubiquitin Receptor Rpn13

Blockade of Ubiquitin Receptor Rpn13 in Plasmacytoid Dendritic Cells Enhances Anti-Myeloma Immunity

Interaction of Plasmacytoid Dendritic Cells and Myeloma Cells Trigger Tumor Promoting Transcriptional Changes in Multiple Myeloma Cells

Loss-of-Function of Gabarap Impairs Bortezomib-Induced Anti-Tumor Immunity in Multiple Myeloma: Clinical Application

Preclinical Validation of Ubiquitin Receptor PSMD4 As Therapeutic Target in Multiple Myeloma

Preclinical Validation of Alpha-Enolase (ENO1) As a Novel Immunometabolic Target in Multiple Myeloma

Results from Phase 1/2 Trial of Tagraxofusp in Combination with Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma

Blockade of Ubiquitin Receptor PSMD4/Rpn10 Triggers Cytotoxicity and Overcomes Bortezomib-Resistance in Multiple Myeloma

Plasmacytoid Dendritic Cells Trigger Contact-Dependent Tumor Promoting Genetic Alterations in Multiple Myeloma Cells

Targeting Tryptophan Catabolic Kynurenine Pathway Enhances Anti-Tumor Immunity and Cytotoxicity in Multiple Myeloma

OP-106 Horizon — Melflufen Therapy for RRMM Patients Refractory to Daratumumab and/or Pomalidomide; Updated Results and First Report on PFS

Identification of Alpha-Enolase (ENO1) As a Novel Immunometabolic Target in Multiple Myeloma

Targeting Proteasome- Associated Ubiquitin Receptor PSMD4/Rpn10 in Multiple Myeloma

HUWE1 Inhibition As a Therapeutic Strategy to Target MYC in MM

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only